Cargando…
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
BACKGROUND: To assess the efficacy and safety of fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, in metastatic colorectal cancer (mCRC) patients. METHODS: A phase Ib open-label study and phase II randomized, placebo-controlled trial compared the efficacy of fruquintini...
Autores principales: | Xu, Rui-Hua, Li, Jin, Bai, Yuxian, Xu, Jianming, Liu, Tianshu, Shen, Lin, Wang, Liwei, Pan, Hongming, Cao, Junning, Zhang, Dongsheng, Fan, Songhua, Hua, Ye, Su, Weiguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244709/ https://www.ncbi.nlm.nih.gov/pubmed/28103904 http://dx.doi.org/10.1186/s13045-016-0384-9 |
Ejemplares similares
-
A phase Ib/II study of fruquintinib in combination with paclitaxel as the second‐line therapy for advanced gastric cancer
por: Zhang, Yang, et al.
Publicado: (2022) -
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer
por: Qin, Shukui, et al.
Publicado: (2021) -
RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer
por: Wang, Kun, et al.
Publicado: (2023) -
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:
Safety, Efficacy, and Biomarkers
por: Wang, Yakun, et al.
Publicado: (2022) -
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
por: Peng, Zhi, et al.
Publicado: (2020)